Denali Therapeutics Inc. (DNLI)
USD 21.43
(-7.71%)
USD 21.43
(-7.71%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 330.53 Million | 108.46 Million | 48.66 Million | 335.65 Million | 26.67 Million | 129.16 Million |
| Cost of Revenue | 423.87 Million | 7.03 Million | 5.6 Million | 212.61 Million | 193.38 Million | 7.41 Million |
| Gross Profit | -93.34 Million | 101.43 Million | 43.05 Million | 123.04 Million | -166.7 Million | 121.74 Million |
| Operating Expenses | 527.23 Million | 449.2 Million | 344.41 Million | 272.94 Million | 239.86 Million | 175.53 Million |
| Selling, General and Administrative Expenses | 103.35 Million | 90.47 Million | 79.05 Million | 60.32 Million | 46.48 Million | 32.34 Million |
| Research and Development Expenses | 423.87 Million | 358.73 Million | 265.35 Million | 212.61 Million | 193.38 Million | 143.18 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 527.23 Million | 449.2 Million | 344.41 Million | 272.94 Million | 239.86 Million | 175.53 Million |
| Operating Income | -196.69 Million | -340.74 Million | -295.75 Million | 62.71 Million | -213.18 Million | -46.37 Million |
| Interest Expense | - | 14.77 Million | - | - | 15.21 Million | - |
| Income Tax Expense | 30 Thousand | 21 Thousand | -575 Thousand | 823 Thousand | -351 Thousand | 10.13 Million |
| Earnings before Tax | -145.19 Million | -325.97 Million | -291.15 Million | 71.95 Million | -197.96 Million | -36.24 Million |
| Net Income | -145.22 Million | -325.99 Million | -290.58 Million | 71.13 Million | -197.61 Million | -36.24 Million |
| Earnings Per Share Basic | -1.06 | -2.60 | -2.39 | 0.65 | -2.07 | -0.39 |
| Earnings Per Share Diluted | -1.06 | -2.60 | -2.39 | 0.63 | -2.07 | -0.39 |
| Weighted Average Shares Outstanding | 137.37 Million | 125.53 Million | 121.52 Million | 108.97 Million | 95.6 Million | 92.62 Million |
| Weighted Average Shares Outstanding (Diluted) | 137.37 Million | 125.53 Million | 121.52 Million | 112.7 Million | 95.6 Million | 92.62 Million |
| Gross Margin | -0.28 | 0.94 | 0.88 | 0.37 | -6.25 | 0.94 |
| EBIT Margin | -0.54 | -3.05 | -6.08 | 0.19 | -7.99 | -0.36 |
| Profit Margin | -0.44 | -3.01 | -5.97 | 0.21 | -7.41 | -0.28 |
| EBITDA | -179.97 Million | -330.36 Million | -287.15 Million | 62.71 Million | -205.19 Million | -38.95 Million |
| Earnings Before Tax Margin | -0.60 | -3.14 | -6.08 | 0.19 | -7.99 | -0.36 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 330.53 Million | -305.04 Million | 1.26 Million | 294.12 Million |
| Cost of Revenue | 1.94 Million | 2.16 Million | 16.72 Million | 2.17 Million | 2.21 Million | 1.35 Million |
| Gross Profit | -1.94 Million | -2.16 Million | 313.8 Million | -307.22 Million | -950 Thousand | 292.76 Million |
| Operating Expenses | 114.65 Million | 130.09 Million | 510.5 Million | 130.39 Million | 115.06 Million | 123.64 Million |
| Selling, General and Administrative Expenses | 23.25 Million | 23.07 Million | - | 22.59 Million | 25.32 Million | 26.12 Million |
| Research and Development Expenses | 91.39 Million | 107.01 Million | - | 107.8 Million | 89.73 Million | 97.52 Million |
| Other Expenses | -14.36 Million | - | - | - | - | - |
| Cost and Expenses | 116.59 Million | 132.25 Million | 527.23 Million | 132.57 Million | 115.06 Million | 123.64 Million |
| Operating Income | -116.59 Million | -132.25 Million | -196.69 Million | -132.57 Million | -113.79 Million | 170.48 Million |
| Interest Expense | - | - | - | 21.08 Million | - | - |
| Income Tax Expense | - | 2.11 Million | 30 Thousand | 30 Thousand | 2.25 Million | -2.28 Million |
| Earnings before Tax | -99.02 Million | -101.8 Million | -145.19 Million | -119.44 Million | -99.35 Million | 183.38 Million |
| Net Income | -99.02 Million | -101.8 Million | -145.22 Million | -119.47 Million | -99.35 Million | 183.38 Million |
| Earnings Per Share Basic | -0.59 | -0.68 | - | -0.86 | -0.72 | 1.34 |
| Earnings Per Share Diluted | -0.59 | -0.68 | - | -0.86 | -0.72 | 1.30 |
| Weighted Average Shares Outstanding | 168.83 Million | 149.4 Million | 137.37 Million | 138.24 Million | 137.64 Million | 137.04 Million |
| Weighted Average Shares Outstanding (Diluted) | 168.83 Million | 149.4 Million | 137.37 Million | 138.24 Million | 137.64 Million | 140.93 Million |
| Gross Margin | - | - | 0.95 | 1.01 | -0.75 | 1.00 |
| EBIT Margin | - | - | - | 0.43 | -88.06 | 0.58 |
| Profit Margin | - | - | -0.44 | 0.39 | -78.42 | 0.62 |
| EBITDA | -114.65 Million | -130.09 Million | - | -130.39 Million | -111.57 Million | 170.48 Million |
| Earnings Before Tax Margin | - | - | -0.60 | 0.43 | -89.81 | 0.58 |
PANACEABIO
6301
8898
O
5133
PES